The IBM® MarketScan® Dental Database is a patient-level linked dental and medical insurance claims database that contains ~28.6 million covered lives. Established in 2005, this database is used for longitudinal and comparative analyses of diseases, treatment patterns, costs, duration of therapy, concomitant therapies, and other research purposes.
Email: RWDassets@iqvia.com
N/A
To find information regarding publications please visit: https://www.imsheorbibliography.com/ or contact IQVIA.
Email: RWDassets@iqvia.com
N/A
To find information on publications please visit: https://www.imsheorbibliography.com/ or contact IQVIA for the most recent publications.
Email: RWDassets@iqvia.com
N/A
To find information on publications please visit: https://www.imsheorbibliography.com/ or contact IQVIA
Email: RWDassets@iqvia.com
N/A
Very new database; publications pending. However, you may contact IQVIA for more information.
Luke Boulanger
Lead Offering Manager, MarketScan
Merative
Email: lboulang@merative.com
Email: marketscan.support@merative.com or fill out form at
https://www.merative.com/contact
1. Tranby EP, Frantsve-Hawley J, Minter-Jordan M, Thommes J, Jacob M, Monopoli M, Okunev I, Boynes SG. A cross-sectional analysis of oral health care spending over the life span in commercial- and Medicaid-insured populations. J Am Dent Assoc. 2021 Nov 9:S0002-8177(21)00486-4.
2. Chua KP, Hu HM, Waljee JF, Brummett CM, Nalliah RP. Opioid prescribing patterns by dental procedure among US publicly and privately insured patients, 2013 through 2018. J Am Dent Assoc. 2021 Apr;152(4):309-317.
3. Nasseh K, Fosse C, Vujicic M. Comparative analysis of dental procedure mix in public and private dental benefits programs. J Am Dent Assoc. 2021 Oct 1:S0002-8177(21)00482-7.
4. Chua KP, Kenney BC, Waljee JF, Brummett CM, Nalliah RP. Dental Opioid Prescriptions and Overdose Risk in Patients and Their Families. Am J Prev Med. 2021 Aug;61(2):165-173.
5. Thornhill MH, Gibson TB, Durkin MJ, Dayer MJ, Lockhart PB, O'Gara PT, Baddour LM. Prescribing of antibiotic prophylaxis to prevent infective endocarditis. J Am Dent Assoc. 2020 Nov;151(11):835-845.e31.
6. Zhou J, Calip GS, Rowan S, McGregor JC, Perez RI, Evans CT, Gellad WF, Suda KJ. Potentially Inappropriate Medication Combination with Opioids among Older Dental Patients: A Retrospective Review of Insurance Claims Data. Pharmacotherapy. 2020 Oct;40(10):992-1001.
ADOReg is a nationwide German prospective registry for health services research in dermatologic oncology. The skin cancer registry ADOReg was developed by ADO and ONKODATAMED GmbH working in collaboration - in 2014. The data come from skin cancer treating sites (59 as of 2021) which treat ~8,500 patients, who have one of the following types of skin cancer:
- Malignant Melanoma
Do you have a general request or a specific inquiry? Please feel free to contact ADOREG staff by sending an e-mail to
support@adoreg.de, or you may call them at the following phone numbers in Germany:
Support: +49 30 800 930 8-50
Office: +49 30 800 930 8-30
N/A
1. Jiang R, Weichenthal M, Fernandez-Lazaro CI, Rudolph A, Krepler C, Mohr P. HSR24-154: Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy—An Analysis of the ADOReg German Skin Cancer Registry. Journal of the National Comprehensive Cancer Network. 2024 Apr 5;22(2.5).
2. Kochanek C, Gilde C, Zimmer L, Ugurel S, Meier F, Utikal J, Pföhler C, Herbst R, Haferkamp S, Welzel J, Dücker P, Leiter U, Weichenthal M, von Wasielewski I, Angela Y, Gutzmer R. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG. Eur J Cancer. 2024 Feb;198:113508.
3. Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. J Immunother Cancer. 2023 Apr;11(4):e005828. doi: 10.1136/jitc-2022-005828. Erratum in: J Immunother Cancer. 2024 Jan 31;12(1).
4. Placke JM, Kimmig M, Griewank K, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma–analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM. EBioMedicine. 2023 Oct 1;96.
5. Koch EAT, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, Hassel JC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schlaak M, Thoms KM, Ugurel S, Utikal J, Weichenthal M, Schuler-Thurner B, Berking C, Heppt MV. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial. Front Med. 2023 Oct;17(5):878-888.
6. Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, Mohr P, Kähler KC, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, Gutzmer R, Debus D, Schilling B, Kreuter A, Ulrich J, Meiss F, Herbst R, Forschner A, Leiter U, Pfoehler C, Kaatz M, Ziller F, Hassel JC, Tronnier M, Sachse M, Dippel E, Terheyden P, Berking C, Heppt MV, Kiecker F, Haferkamp S, Gebhardt C, Simon JC, Grabbe S, Loquai C. Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. J Immunother Cancer. 2023 Sep;11(9):e007630. doi: 10.1136/jitc-2023-007630.
7. Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, Forschner A, Leiter U, Ulrich J, Utikal J, Welzel J, Kaatz M, Gebhardt C, Herbst R, Sindrilaru A, Dippel E, Sachse M, Meiss F, Heinzerling L, Haferkamp S, Weishaupt C, Löffler H, Kreft S, Griewank K, Livingstone E, Schadendorf D, Ugurel S, Zimmer L. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. Eur J Cancer. 2023 Jul;188:140-151.
8. Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. J Immunother Cancer. 2023 Apr;11(4):e005828.
9. Glutsch V, Schummer P, Kneitz H, Gesierich A, Goebeler M, Klein D, Posch C, Gebhardt C, Haferkamp S, Zimmer L, Becker JC, Leiter U, Weichenthal M, Schadendorf D, Ugurel S, Schilling B. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. J Immunother Cancer. 2022 Nov;10(11):e005930.
10. Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, Ugurel S, Placke JM, Weichenthal M, Gutzmer R, Leiter U, Kaatz M, Haferkamp S, Berking C, Heppt M, Tschechne B, Schummer P, Gebhardt C, Grabbe S, Loquai C. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. Cancers (Basel). 2022 Nov 11;14(22):5543.
